Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neurology
Published in: Journal of Neurology 7/2015

01-07-2015 | Letter to the Editors

Acyclovir-related kidney injury during alemtuzumab infusion

Authors: Assunta Bianco, Giovanni Gambaro, Paolo Maria Rossini, Massimiliano Mirabella

Published in: Journal of Neurology | Issue 7/2015

Login to get access

Excerpt

Dear Sirs, …
Literature
1.
2.
Havrdova E, Horakova D, Kovarova I (2015) Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord 8(1):31–45PubMedCentralCrossRefPubMed
3.
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, CARE-MS I investigators (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856):1819–1828CrossRefPubMed
4.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA, CARE-MS II investigators (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380(9856):1829–1839CrossRefPubMed
5.
S, Arnold DL, Johen J, et al (2013). Herpes infection risk reduced with acyclovir prophylaxis after alemtuzumab. Consortium of Multiple Sclerosis Centers 2013 Annual Meeting, 29 May–1 June 2013, Orlando, FL, USA, Poster DX60
6.
Izzedine H, Launay-Vacher V, Deray G (2005) Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 45(5):804–817CrossRefPubMed
7.
Yarlagadda SG, Perazella MA (2008) Drug-induced crystal nephropathy: an update. Expert Opin Drug Saf 7(2):147–158CrossRefPubMed
8.
Lam NN, Weir MA, Yao Z, Blake PG, Beyea MM, Gomes T, Gandhi S, Mamdani M, Wald R, Parikh CR, Hackam DG, Garg AX (2013) Risk of acute kidney injury from oral acyclovir: a population-based study. Am J Kidney Dis 61(5):723–729CrossRefPubMed
9.
Htwe TH, Bergman S, Koirala J (2008) Famciclovir substitution for patients with acyclovir-associated renal toxicity. J Infect 57(3):266–268CrossRefPubMed
10.
Domagała A, Kurpisz M (2001) CD52 antigen–a review. Med Sci Monit 7(2):325–331PubMed
Metadata
Title
Acyclovir-related kidney injury during alemtuzumab infusion
Authors
Assunta Bianco
Giovanni Gambaro
Paolo Maria Rossini
Massimiliano Mirabella
Publication date
01-07-2015
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 7/2015
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-015-7786-4

Other articles of this Issue 7/2015

Journal of Neurology 7/2015 Go to the issue

ACKNOWLEDGEMENT

Acknowledgement to Reviewers 2014

Original Communication

Thyroid hormone level is associated with motor symptoms in de novo Parkinson’s disease

Neurological Update

On visual hallucinations and cortical networks: a trans-diagnostic review

Original Communication

Clinical variability in ataxia–telangiectasia

Letter to the Editors

Impulsive aggressive obsessions following cerebellar strokes: a case study

Short Commentary

Psychiatric disorders, spinocerebellar ataxia type 3 and CAG expansion